Pharma Journalist

5th Annual Injectable Drug Delivery Conference
2023-05-10 - 2023-05-11 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
Exploring Injectable Drug Formulations and Device Development
Sponsors: Victrex
Exhibitors: PHC Group
As Part of Europe’s leading Injectable conference series, the 5th annual Injectable Drug Delivery conference will assess innovations in drug product formulation and biologics, new technologies in device design, along with the latest regulatory considerations for optimal drug delivery.

With increasing demand for vaccines, insulin, and many other modern medicines administered via the injectable route, there is significant growth projected in the biologics market, particularly the injectable drug delivery and prefilled syringe market which is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. It is due to this rising demand and increased growth that the industry must come together to discuss and critically evaluate the next generation of injectable drug delivery.
At this year’s event we will highlight the most recent innovations within the industry, with regard to injectable device design and the formulation challenges of long-lasting, highly viscous and high-volume drug delivery. In silico modelling will be addressed as we continue to see a move towards AI utilisation, alongside key CMC concerns and usability of injectable devices in digital health. The conference will also highlight the significance of sustainability within the industry, whilst providing regulatory insight on the changes that have occurred and are forecast in the coming years.
Benefits of attending:

Explore the latest trends within the Injectable drug delivery field, with new insights into in-silico modelling
Expand on current knowledge of device design, with special considerations for primary and secondary packaging
Examine injectable drug formulation strategies, including novel formulation methodologies
Learn how to advance the injectable drug delivery landscape through a review of current regulatory compliance
Realise how Chemical Manufacturing and Control can further expand the industry through digitalisation strategies

To know more visit: http://www.injectable-drug-delivery.com/PharmaJournalist-EI

Highly Potent Active Pharmaceutical Ingredients Conference 2023
2023-05-10 - 2023-05-11 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety.
Our 2023 conference brings insights from leading pharmaceutical companies on how to improve hazard identification, integrate advanced containment controls and mitigate the risk of manufacturing HPAPI. Featuring leading speakers including directors, engineers, and experts in validation requirements this conference provides an extensive look at how you can futureproof your pharmaceutical manufacturing facilities.
This two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies.
Benefits of Attending the HPAPI Conference:

LEARN how to ensure advanced therapeutic manufacturing is safe for workers and patients
INCREASE the effectiveness of your engineering containment controls by improving harmony between the worker engineer and toxicologist to ensures cost-effective design choices
UNCOVER the best practises & opportunities for pharmaceutical companies to work alongside CMOs to effectively and efficiently scale-up HPAPI manufacturing
REVIEW case studies on the implementation of risk-based hazard identification strategies from leading pharmaceutical companies including AstraZeneca, CSL Behring and Merck

DISCOVER future trends in containment and control technologies to future-proof your HPAPI manufacturing plant to maximsie operator safety
To know more visit: www.highlypotentapi.com/PharmaJournalistEL

4th STING & TLR Targeting Therapies Summit
2023-05-09 - 2023-05-11 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Facilitating key conversations needed to drive forward the development of safe and effective innate stimulating immunotherapies, the 4th STING & TLR Targeting Therapies Summit will take place, for the first time ever in person, in Boston on May 9-11, 2023.
View the official program here.
Explore innate agonists from discovery to translation with the leaders in the space and gain insight into clinical updates, unpack what went wrong with some failures like ADU-S100 and address critical challenges including driving down toxicity, preclinical model selection and choosing appropriate delivery mechanisms.
Here are some exciting highlights you cannot miss including:

Reviewing the clinical landscape in the past year, key updates in innate agonists that have moved through the clinic, and identifying the root of failed trials through integral discussions led by Beacon Targeted Therapies, Tempest Therapeutics, and #Indaptus Therapeutics
Assessing the best innate agonist delivery approaches, from data on antibody-conjugated STING agonists with Takeda Oncologyand ImmuneSensor to unpacking 7&8 Biopharma’s IV delivery to extracellular vesicle approaches with Codiak Bio
Revisiting cancer vaccines and navigating their development with post-COVID vaccine considerations; with Elicio Therapeuticsand UT Southwestern Medicine, exploring the use of STING / TLR adjuvants to deliver on this promising therapeutic
Venturing beyond oncology to learn from drug developers utilizing STING & TLR agonists to treat infectious diseases and adding these potent innate activators to our arsenal to be better equipped for the next pandemic

View the complete agenda and speaker line-up.
Being the only meeting dedicated to driving forward the development of innate immune agonists, we encourage you to take this exciting opportunity to unite and leverage the industry’s cumulative knowledge and experience to have meaningful conversations that will translate STING & TLR agonists into effective and reliable treatment options.

4th Annual Gene Therapy Analytical Development Europe Summit 2023
2023-05-02 - 2023-05-04 | The Tower Hotel, St. Katharine's Way, London, E1W 1LD, United Kingdom
Uniting leading CMC, Regulatory, QC, Analytical and Process Development experts, the 4th Annual Gene Analytical Development Europe Summit is the industry’s definitive and only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development.
Hear from the likes of AstraZeneca, MHRA, Gyroscope, REGENXBIO, Biogen, Spark Therapeutics, and more across three days and two tracks of in-depth case studies, interactive panel discussions, dedicated Q&A time, and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field.
Don’t miss the opportunity to network with 80+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle.
To know more visit: https://ter.li/q8u3rf

6th Annual Pharmaceutical Microbiology USA Conference
2023-04-26 - 2023-04-27 | Boston, MA, USA
6th Annual Pharmaceutical Microbiology USA Conference
April 26 – 27, 2023
Boston, MA, USA
http://www.pharma-microbiology-usa.com/PharmaJournalistWL
Sponsored by: LONZA
Chaired by: Donald Singer, USP General Chapter Committee Microbiology Chair, US Pharmacopeia
Contamination Control and Microbial Methods Explored to Assure Product Quality and Prevention
Microbiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches.
Ensuring the sterility of the finished product continues to be one of the most critical aspects of drug development, however an array of factors is also sustaining new growth and transformation in this field. The regulatory landscape is changing, firstly with the preparation of Annex I, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement.
On top of this, the developing integration of automation and robotics into the manufacturing pipeline, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs, are all highlighting the necessity of the field in Pharma.
This industry is ever expanding, join our leading experts at the 6th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with the industry professionals, discuss revisions in regulatory and guidance documents, and gain a deeper insights.
Event Hashtag: #MicrobiologyUSA
Key Conference Highlights:

Review implementation guidance and validation for efficient microbial testing programs
Uncover how to implement effective contamination control for manufacturing and the impact throughout pharmaceutical microbiology
Learn how to control mold contamination and apply risk-based tools to tackle recovery
Delve into the role the microbiologist plays in bioburden assessments and holistic closure integrity testing for new drug modalities
Understand innovative techniques to control contamination as it relates to cell therapy products, combination, and traditional microbiological drug products

View the full agenda: http://www.pharma-microbiology-usa.com/PharmaJournalistWL

2nd ADC Analytical Development Summit 2023
2023-04-25 - 2023-04-27 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 2nd ADC Analytical Development Summit (April 25-27, 2023 | Boston, MA) is the only meeting focused on optimizing the application of analytical technologies for ADC, from drug-linker and drug substance through to drug product to guide regulatory specifications and submissions, to enhance understanding of your drug and to exert control over your process.
See the complete 2023 event guide here.
With many new ADCs under development, the analytical challenges are only increasing as the existing hurdles keep changing, with the regulatory guidance still being limited. This is a unique touch point for drug developers to discuss the core analytical challenges the industry is facing including drug linkers, drug substances, drug formulation, and drug products.
You and your team can expect to leave this meeting equipped to have a deeper understanding of your drug and confidently enter conversations with regulators with thought-provoking insights from our expert speaker faculty including:

Yuan Gao, Head of Analytical Development, ADC Therapeutics
Jessica Webb, Scientist, Analytical Sciences, AstraZeneca
Guifeng Jiang, Head of Analytical Development Pharmaceutical Operation, Bolt Biotherapeutics
Thomas Gardinier, Head of Materials Analysis, Elucida Oncology
Simon Letarte, Director, Gilead
Adrienne Wildt, Senior Director of Analytical Development, ImmunoGen
Shuwen Sun, Principal Scientist, Merck & Co
Vimal Patel, Vice President, Head of CMC & Supply Chain, Orum Therapeutics
Julie Beaudet, CMC Staff Scientist, Regeneron Pharmaceuticals
Sarah Owen, Senior Scientist Potency Assays, Seagen
Melvin Flores, Director Quality Control Analytical & Microbiology, Sutro Biopharma
May Zhu, Director of Analytical Development- External Interface Management, Takeda

Join them here.
With 100+ attendees, 4+ hours of dedicated networking, and 3 days of exciting new content, including a pre-conference focus day on comparability studies, this is a conversation you won’t want to miss to hopefully, increase knowledge on your ADC quality attributes to understand and strive for regulatory approval

Gene Therapy Durability Summit
2023-04-25 - 2023-04-27 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Uniting the leading minds in gene therapy at the Gene Therapy Durability Summit, join us to:

Leverage knowledge from current clinical trials with relevant durability data across a range of indication types using AAV
Better understand what can be extrapolated and how to gain confidence in the data collected
Build study designs with durability in mind and explore how well preclinical models have predicted clinical durability to date

Hear from the likes of Pfizer, Selecta Biosciences, Spark Therapeutics, Rocket Pharmaceuticals, ASC Therapeutics and more across a preconference workshop day, expert presentations, interactive panel discussions, dedicated Q&A time and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field.
When you attend you will:

Understand the regulatory requirements to determine robust durability
Explore the challenges short term immunogenicity has on durability
Navigate how to overcome long term immunogenicity concerns on durability
Optimize vectors constructs to maximize gene therapy durability
Discover how to better predict the translational success of durability when progressing from preclinical to clinical trials

Register to attend with your colleagues and get up to 20% off your tickets – https://ter.li/oeczu3

5th Neuroimmunology Drug Development Summit
2023-04-25 - 2023-04-27 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
With increasing prioritization for neuroscience discovery, huge biopharma is investing in expanding its departments, focusing on glial biology, neuroinflammatory biomarkers, and optimizing various approaches to target the likes of LRKK2, TREM2, and more. Therefore, there is a great amount of novel and promising research to be discussed in 2023.
Uniting 100+ neuroinflammation and neuroimmunology experts across all neurological indications, including AD, PD, ALS, and MS, the 5th Annual Neuroimmunology Drug Development meeting will return to Boston to host discovery, preclinical, translational, and clinical experts from the likes of Genentech, Muna Therapeutics, Biogen, Janssen, Bristol Myers Squibb, Sanofi, Takeda, and Roche.
With new speakers from the hottest biopharma in neuroimmunology delivering, a comprehensive program of pioneering and cutting-edge content, don’t miss your crucial chance to join this niche audience of innovators with a shared desire to explore strategy, creation, and implementation of research, biomarker, and clinical hypothesis testing in neuroimmunology.
To know more visit: https://ter.li/w642sd

5th Cell Engager Summit
2023-04-25 - 2023-04-27 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 5th Annual Cell Engager Summit is back in Boston, MA this year – the only industry-led meeting bringing together 100+ pharma and biotech leaders will assemble for a 3-day agenda including 4 unique pre-conference workshops to delve into the biggest challenges cell engager therapeutics face. Breaking into the solid tumor, preventing CRS and maximizing the quality of insights we gain from preclinical modeling.
For unmissable opportunities, including:

Gain first-hand knowledge of the difficulties of developing kinase inhibitors to improve selectivity, cross the blood-brain barrier, and combat resistance
Utilize cutting-edge platforms and technologies to maximise target validation and precisely predict off-target impacts to save time and costs
Establish long-lasting relationships by speaking with top pharma and biotech firms that are working on kinase inhibitor medicines and looking for the best-in-class solutions directly

Join your colleagues from the likes of Apexigen, Regeneron Pharmaceuticals, Genentech, Roche, Amgen, Boehringer Ingelheim and many more at the most comprehensive cell engager event, leaving no stone unturned, this highly focussed meeting covers everything translational and clinical in greater depth and detail than any before it.
Download the full event guide for your sneak peek.

Next Generation Cardiovascular Drug Development Summit
2023-04-25 - 2023-04-27 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
Welcome to the Next Generation Cardiovascular Drug Development Summit
Executing Cell & Gene Therapy for Cardiac Regeneration
Following technology advancements and the surge of investment in developing the next generation of cardiovascular disease drugs, the opportunity to successfully leverage our knowledge of CRISPR/Cas9, siRNA, autologous iPSC therapy, capsid engineering, and digital medicine to reduce the soaring fatality rate has never been closer.
The Next Generation Cardiovascular Drug Development Summit in Boston is the only industry-led summit committed to overcoming preclinical challenges to advance your ischemic heart disease, arrhythmogenic cardiomyopathy, strokes and hypertension pipelines.
To know more visit: https://ter.li/s7qk9l

10th Annual Pre-Filled Syringes East Coast Conference
2023-04-24 - 2023-04-25 | Boston, USA
10th Annual Pre-Filled Syringes East Coast Conference
April 24 – 25, 2023
Boston, USA
Driving Innovations in Device Design, Connectivity and Sustainability for Advanced Parenteral Combination Product
https://www.pfsamericas.com/PJ-Event-listing
The 10th annual Pre-Filled Syringes East Coast conference will once again play host to an international audience of drug delivery, medical device and PFS experts to discuss emerging trends and offer innovative solutions to the challenges facing the pre-filled syringes industry, helping attendees to secure global success for their devices.
The past year has seen significant developments in the injectables landscape with the evolving regulatory landscape, accelerating opportunities in digitilization and simulation to improve device design efficiency, and increased opportunities for connectivity to improve the user experience.
Furthermore, with a growing need for circular economy, this year’s conference will assess case studies of sustainable approaches for device packaging and life cycle management, while panel discussions, FDA and BioPhorum addresses will evaluate current and upcoming combination product guidelines and the potential for harmonization.
As part of SAE Media Group’s leading drug delivery portfolio of events, this event will bring you the key insights you need to expand and enhance your injectable device portfolio and the opportunity to network with senior players throughout the industry.
Benefits of Attending:

Discover the latest industry developments for improved large volume and high viscous delivery via advanced autoinjector and on body delivery system design
Assess the growing opportunities of digitalization and simulation for improved device development efficiency and potential
Engage in an FDA regulatory roundup from the office of combination products, insights into EPR identification from BioPhorum and a panel discussion assessing harmonization of the regulatory landscape
Delve into emerging technologies in injectable device design and case studies on digital integration of medical devices for improved user experience

Benchmark against sustainable device packaging case studies driving the combination product industry towards circular economy

mRNA Process Development & Manufacturing Europe
2023-04-18 - 2023-04-20 | Sheraton Offenbach Hotel, Am Buesing Palais, Berliner Str. 111,, Offenbach am Main, 63065, Germany
mRNA therapeutics have catapulted into the limelight amidst the COVID-19 pandemic with multiple EMA approvals to help combat the virus.
Bringing together KOLs sharing case studies with actionable insights, the inaugural mRNA Process Development & Manufacturing Summit Europe has been established as the first forum in Europe to support your in-house process development and manufacturing strategies.
The 3-day agenda has been carefully co-authored along with the leaders within the industry from the likes of BioNTech, AstraZeneca and Genentech. A snapshot of key topics include:

Assessing how dsRNA formation can be limited to reduce the purification requirements of the manufacturing process with BioNTech SE
Uncovering how to maximise biocomparability when scaling up the batch manufacturing process, including identifying the critical process steps that introduce batch-to-batch variability with Genentech & Roche
A snapshot of robust, high-throughput online novel assays for identifying impurities with CureVac & AstraZeneca
Understanding critical quality attributes and the differences in process development considerations for mRNA therapeutics and vaccines to achieve appropriate drug substance quality with the University of Sheffield & University Hospital Zurich
Hearing how the global market could function with a standard process platform to benefit all patients with Medicines Patent Pool

This is an opportunity to join 80+ mRNA enthusiasts from mRNA manufacturing, analytics, process development, CMC, quality control, and drug substance to get key insights on scaling up mRNA drug substances in Europe whilst navigating mRNA process development and manufacturing regulatory guidelines to create commercially successful mRNA vaccines and therapeutics.
To know more visit: https://ter.li/f3ec38

3rd Fc Receptor Pathway Targeted Therapies 2023
2023-04-18 - 2023-04-20 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx, Janssen, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity.
The 3rd Fc Receptor Pathway Targeted Therapies Summit will once again feature unmissable conversations to advance targeting FcR and the subsequent generation of Fc manipulation since real-world proof and clinical value are now at the industry’s fingertips.
Join 100+ of your colleagues at the 3rd Fc Receptor Pathway Targeted Therapies Summit – from the fields of immunology, antibody engineering, pharmacology, toxicology, and immuno-oncology for three days of content that is unmatched in its scope, all focused on the optimization of FcRn, FcγR, and novel Fc.
Put your stake in the ground to revolutionise autoimmune illness and position yourself in front of the next wave of blockbuster drug development.
To know more visit: https://ter.li/y9vxt6

2nd LNP Formulation & Process Development Summit
2023-04-17 - 2023-04-19 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Turbocharging Your Next Gen LNP End-To-End Development to Deliver Curative Promises to Patients
Following exciting industry updates from Verve Therapeutics’ GalNAc-LNP for PCSK9 for HFpEF treatment, to Recode’s 5th element, the 2nd LNP Formulation & Process Development Summit is your must-attend meeting as this nanoparticle continues to dominate the biopharmaceutical industry in 2023.
New for 2023, we have curated 3 streams of content for 2nd iteration of the summit:

In depth discussions divulging IP and regulatory compliance for LNP drug products
Maximized LNP flexibility and versatility for payloads beyond mRNA vaccines with other RNA, DNA, gene therapy and gene editing possibilities
Lipid Chemistry & Discovery Track: Novel lipid discovery and particle engineering to customize LNP composition for next generation delivery vehicle
Formulation & Process Development Track: Optimize your LNP development techniques for enhanced manufacturability and product quality, and overcome stability issues of LNP-nucleic acid drug products
LNP CMC & Manufacturing Track: Elevating your process control, CQAs framework for CMC, GMP compliance for seamless scale-up

This summit will offer the most comprehensive content and exclusive data, equipping you with end-to-end LNP development journey to exploit this lucrative non-viral delivery vehicle for various payloads to your destined cells and organs.
In collaboration with Intellia Therapeutics, Pfizer, Sanofi, ReCode Therapeutics, Akagera Medicines, the 2nd LNP Formulation & Process Development Summit is committed to serving you with their lessons learned to supercharge your pipeline and deliver curative promises to patients.
Join us to stay at the forefront of science, network with 350+ LNP Biology, Chemistry, Formulation & Process Development, Tech Ops & Manufacturing experts to gain competitive advantage to exploit LNP potentials!
To know more visit: https://ter.li/ol6e27

3rd Annual Ligase Targeting Drug Development Summit
2023-04-11 - 2023-04-13 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Hijacking E3 Ligases to Mediate Degradation & Modulation of Undrugged Targets
As a family of over 600 known proteins, ligases pose immense potential as viable avenues for harnessing previously undrugged targets. Key challenges remain however to rapidly discover and identify novel and underexploited ubiquitin E3s. Furthermore, bottlenecks exist in the development of the established ligases; Cereblon and VHL.

It is now critical that we harness Cryo-EM, X-Ray crystallography, and other visualization tools to fully understand the structure and function of these lesser-known E3s, accelerate ligand screening with new and improved tools, leverage advances in DMPK knowledge to address concerns over toxicity in Cereblon, propel VHL from ‘academic’ to clinic, and all in, de-risk the translation of candidate ligases to the clinic.
The 3rd Ligase Targeting Drug Development Summit is returning with fresh understanding and data from the forerunners of the field and those who have recently joined the space. Together we will investigate ligase structural and functional biology, screening tools for optimal ligase, linker, and ligand identification, explore tissue specificity, uncover the key modalities where ligases can succeed, and showcase the novel assays that are maximizing validation to ensure success in the clinic.
This dedicated forum will provide an unrivaled meeting point for industry leaders all under one specialized forum to strategically accelerate and de-risk the process of identifying, validating, and therapeutically leveraging cell and tissue-specific ubiquitin E3 ligases for degradation or modulation of targets in oncology, immunology, and beyond.
To know more: https://ter.li/gapgsb

4th TCR-based Therapies for Solid Tumors Summit
2023-04-03 - 2023-04-05 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
The first TCR-based therapy approval in the US and Europe at the start of last year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it’s time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.
The 4th TCR-based Therapies for Solid Tumors Summit is returning to Boston as the must-attend forum for TCR experts to come together to share industry updates and next generation engineered approaches to boost therapy safety and efficacy.
Join leaders and newcomers including Immunocore, Medigene, Immatics, Captain T Cell and Anocca as they collaborate to guarantee tumor-specificity, prevent cross-reactivity, boost TCR and target discovery, enhance solid tumor durability and explore TCR modalities.
Huge milestones were achieved for the TCR field in 2022, however, there’s no time to sit back and relax. Collaborate with like-minded TCR trailblazers to secure clinical validation and streamline the road from discovery to commercialization.
To know more visit: https://ter.li/h6mn96

8th Innate Killer Summit
2023-03-28 - 2023-03-30 | HILTON LA JOLLA TORREY PINES, 10950 N. Torrey Pines Road, La Jolla, CA, 92037, United States
Dedicated to driving cost-effective, efficacious, safe, durable, scalable, and globally accessible allogeneic, cell-based, and engager therapies, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics. Your industry-defining Innate Killer Summit brings crucial insights for everyone on your team, with 4 content tracks spanning preclinical development, clinical translation, CMC, process development, and clinical scale manufacturing, this is the definitive meeting to drive concept to commercial success of emerging innate immune therapies.
Download your copy of the Full Event Guide here.
Join over 250 experts from 120+ pioneering companies to drive novel gene engineering technologies, gain regulatory know-how, optimize lymphodepletion and cryopreservation, and contrast cell sources for highly efficacious, scalable off-the-shelf therapies.
Promising brand-new speakers from new companies, interactive discussion, and engaging networking opportunities, attend to forge new collaborations and realize the clinical potential of innate immune therapies.
Register your place here.

Reuters Events: Pharma USA 2023
2023-03-28 - 2023-03-29 | Pennsylvania Convention Center, 1101 Arch St, Philadelphia, PA, 19107, United States
Patient-first. Collaborative. Data and insights driven. Digitally underpinned.
These are the qualities of a healthcare system that actively serves its purpose – yet instead, the US is hindered by mounting financial toxicity, unprecedented politicization of science and eroding public trust.
To capitalize on three years of extraordinary momentum and lead healthcare’s reform, pharma must embody the traits that healthcare needs to thrive and restructure in pursuit of change.
Seize the moment at Reuters Events: Pharma USA 2023 to lead pharma’s internal revolution and drive this critical systemic transformation. Join North America’s visionary pharma changemakers, leading solution providers, patient experts and industry heavyweights to catapult commercial excellence, ingrain patient-first strategies into the heart of pharma’s fabric and heed the long-awaited rebirth of America’s healthcare system.
To know more visit: https://bit.ly/3uJUp5O

6th Annual Gene Therapy for Rare Disorders 2023 Summit
2023-03-20 - 2023-03-23 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
As the gene therapy field continues to break records, there are still significant challenges to overcome relating to safety, efficacy, and accessibility. The 6th Annual Gene Therapy for Rare Disorders 2023 Summit remains devoted to showcasing the top case studies and strategic learnings from the past year. With an expert speaking faculty devoted to bringing safer and more effective gene therapies to rare disease patients, key questions will be answered on how best the field can overcome regulatory, clinical, manufacturing and pricing bottlenecks to progress gene therapies into and through the clinic.
500+ leading experts from innovative biotechs, large pharma, academia and key service providers will be reuniting in Boston for 2023 to capitalize on recent success stories and collaborate over the most pressing industry challenges. An event vital to unlocking the full potential of your rare gene therapy program, join us to keep your finger on the pulse and set up for success in 2023.
To know more visit: https://ter.li/bvmkei

SAE Media Group Proudly Presents the 4th Annual AI in Drug Discovery Conference
2023-03-13 - 2023-03-14 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
SAE Media Group is proud to present its 4th Annual AI in Drug Discovery Conference, taking place from 13 – 14 March 2023 in London, UK.
With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts.
AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
The uptake of structure-based target selection and innovative in-silico techniques are driving optimised, more efficient drug discovery. This, alongside sessions on automation, robotics and how to improve patient-centricity in precision medicine are just some of the topics set to be discussed which you wouldn’t want to miss at the 4th annual AI in Drug Discovery Conference 2023.
Our influential line-up of speakers will be taking to the stage from 13 – 14 March 2023 at the Copthorne Tara Hotel, London to provide you with the latest insights and advice for you to take back to your business.
Key Reasons to Attend:

DELVE into key industry research focuses, with talks on fragment-based selection, in silico drug design and personalised medicine from GSK, Bayer, Janssen Pharmaceuticals and more
INCREASE the diversity of your drug discovery programme with case studies in applying knowledge graphs, molecular dynamic simulations, and digital twins throughout the development process
UTILISE breakthroughs in robotics, automation and quantum chemical methods alongside AI to drive the next generation of drug discovery
UNCOVER the role that international cooperation and open-source data played in the rapid development of Covid-19 treatments, and how this can be an example for the future of pharmaceutical R&D
LEARN how to implement AI and Machine Learning techniques throughout the discovery pipeline from antigens and genomics to proteins and peptides

To know more visit: www.ai-indrugdiscovery.com/PJ-EL

Targeted Intracellular Delivery Summit
2023-03-08 - 2023-03-09 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Achieve Therapeutic Localization with Selective, Effective & Validated Delivery to Intracellular Targets
Optimize Your Pipeline’s Therapeutic Index with Novel Delivery Systems to Overcome Endosomal Barriers in Target Cells
Selective cell entry, biological barriers and complexities in targeting chemistry have long restricted the ability of promising drug candidates to impactfully engage their intracellular sites of action without off-target toxicity implications.
Fast forward to 2023, advances in nanomedicine technology, the LNP enabled mRNA vaccine and emphasis on personalized medicine has triggered significant pipeline shifts towards complex nucleic-acid and biologic candidates. This clinical translation depends on novel delivery systems accessing previously elusive intracellular compartments. This is further evidenced by AstraZeneca, Boehringer Ingelheim and Eli Lilly’s announcements of prioritized strategic investment in targeted intracellular delivery technologies.
At such a pivotal moment for the industry, the Targeted Intracellular Delivery Summit arrives to bring Formulation, Chemistry, Delivery & Biology industry professionals to the forefront of cutting-edge science critical to accelerate pharmaceutical R&D. Join 80+ senior leaders to explore target identification, tissue delivery, engineering technologies, endosomal escape, delivery validation analytics and more.
This is your definitive meeting for unpresented data, unrivalled insights and unmissable methodologies across the next-generation nano-platforms including LNPs, EVs, Liposomes & more, creating new opportunities for the development of safer and efficacious oligonucleotide, siRNA, mRNA, DNA delivery and protein payloads.
Unleash the true potential of your pipeline by gaining the best picture of industry’s fast-paced nano-platform progress this March!
To know more visit: https://ter.li/i23a5q

2nd Next Generation Kinase Inhibitors Summit
2023-02-22 - 2023-02-23 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Since Kinase inhibitors have proven to be efficacious and approvable targets, fuelling recent investment into this exciting space as their therapeutic targeting is explored beyond oncology. However, increasing resistance to existing programs and safety bottlenecks threaten further progress. The next wave of kinase targets depends on innovation.
Join the 2nd Next Generation Kinase Inhibitors Summit to connect with experts across discovery, R&D, and clinical medicine to discuss how to accelerate the next generation of kinase inhibitor drugs to market, which displays maximal therapeutic efficacy and durable clinical responses.
Key Topics:

Assay Development, Kinome Exploration & and Kinase-Focussed Drug Discovery Principles
Overcoming Tumor Resistance, Managing the Tumor Microenvironment, and Improving Durability
Exploiting the RAS/MAPK Signalling Pathway
Multikinase and Combination Therapies to Overcoming Resistance
Targeting Established Pharmacological Mechanisms in Alternative Indications Beyond Oncology to Meet Unmet Needs

Don’t miss this opportunity to join & network with 100+ Kinase Biology Experts under one roof, hear from 18+ expert speakers from the space and showcase your work at the Scientific Poster Session.
This meeting is FREE for drug developers and researchers!
To know more visit: https://ter.li/sreltb

11th Alzheimer’s & Parkinson’s DD Summit
2023-02-21 - 2023-02-23 | Hyatt Centric Fisherman’s Wharf, San Francisco, United States
Welcome to the 11th Alzheimer’s & Parkinson’s Drug Development Summit

With a surge in preclinical investment, fresh news of clinical pipeline progressions, and a new era of therapies pending FDA approvals from Biogen, Eisai, and Denali Therapeutics, 2022 has put neurodegenerative drug development back on the map.
Building on the field’s momentum, we are delighted to bring back the 11th Alzheimer’s & Parkinson’s Drug Development Summit, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery, preclinical, translational, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer’s, Parkinson’s, and related neurological disorders in 2022 and 2023
To know more visit: https://ter.li/x0w74p

3rd Annual Gene Therapy for Muscular Disorders Summit
2023-02-21 - 2023-02-23 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.
This year’s summit will return to Boston to reunite 100+ leading experts in biotech, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells.
This summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials, enabling you to address and overcome these challenges.
To know more visit: https://ter.li/wi2a51

6th CAR-TCR Summit Europe
2023-02-21 - 2023-02-22 | ExCeL London, Royal Victoria Dock, 1 Western Gateway, London, E16 1XL, United Kingdom
Join us in London this February to connect with those trailblazing the next wave of CAR and TCR based approaches from pre-clinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better, and faster.

Take advantage of cutting-edge innovation from global biopharma leaders in cell armouring, combination approaches and multiplexing gene engineering to improve cell durability and trafficking across allogeneic and solid tumour indications, and leave understanding the technical strategies to build automated, closed-system manufacturing processes to ensure vein to vein time is less than a week.
Promising data-driven case studies outlining next generation product design, clinical trial set-up and manufacturing processes, this meeting is your go-to to comprehensively assess the emerging improvements of CAR and TCR based therapies.
See the full agenda here: https://ter.li/ulbn8o

Retinal Vascular Disease Drug Development Summit
2023-02-21 - 2023-02-23 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Retinal Vascular Disease Drug Development Summit is an event dedicated to creating a community space dedicated to overcoming the current challenges in drug development for retinal vascular diseases.
The management of these diseases has made remarkable advancements in previous years, but the burden on patients remains high, posing a need to develop novel therapeutics and delivery mechanisms that improve the efficacy and durability of anti-VEGF drugs and beyond.
Providing you with an in-depth coverage of technical insights of anti-VEGF, innovative non-VEGF targeting therapeutics for wet-AMD, DME, DR and RVO, the Retinal Vascular Disease Drug Development Summit will address the specific challenges in utilizing preclinical models for retinal vascular disease, understand key regulatory requirements, and learn how to run effective clinical trials that utilize appropriate endpoints.
Join your colleagues from across R&D, preclinical, translational and clinical teams across the biopharmaceutical industry to streamline your drug development and address the significant and increasing unmet medical need.
To know more visit: https://ter.li/7xp7xc

CRISPR AgBio Congress 2023
2023-02-14 - 2023-02-16 | The Westin San Diego Bayview, 400 W Broadway, San Diego, CA, 92101, United States
The 5th Annual CRISPR AgBio Congress will unite research heads, molecular biologists, regulatory experts, and product developers from large Ag companies, innovative AgBiotechs, academic groups and regulatory bodies to translate share the challenges and opportunities of translating cutting-edge CRISPR technology into a tangible product. If you are working to advance genome-edited crops or plants, this is the must-attend meeting to network with the leading stakeholders progressing the space forward, keep up with the latest technology advances & guidances, and ensure your product is set up to help meet the significant food security challenges the world is currently facing.
To know more visit: https://ter.li/3nrx25

6th Annual 3D Cell Culture Conference
2023-02-08 - 2023-02-09 | London, UK
6th Annual 3D Cell Culture Conference
8-9 February 2022
London, UK
http://www.3D-cellculture.com/PJwl
Sponsored: CelVivo, Promega and Systemic Bio
Conference Co-chairs:
Phillip Hewitt, Global Head of Early Investigative Toxicology, Merck
Rhiannon David, Director, Microphysiological Systems, AstraZeneca
Exploring the implementation of complex in-vitro models for drug development
Join us in February 2023, as SAE Media Group’s 6th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of clinical applications, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry.
3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.48 Billion by 2028. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process — heralding the next major advance in the discovery of pharmaceuticals.
Event Hashtag: #3DCellCulture2023
Key Conference Highlights:

Discuss the uses of advanced cell technologies for human tissue bioengineering
Uncover the major benefits of 3D modelling in enhancing clinical translation and predictability
Utilise 3D cell culture for personalised drug screening and high-throughput screening over traditional 2D methods
Learn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process
Delve into advanced case studies looking into organ models: from the blood-brain barrier to liver spheroids

Who Should Attend?
Biotech / Pharma Companies – Investigative toxicologist, Research Scientist, Clinical Pharmacologist, Cell Technologists, Cell and Molecular Scientist, Head of Translational Research, In-Vitro Toxicologists, Director of Drug Discovery, Head of DMPK, Chief Scientific Officer, R&D Scientist, Head of R&D.
Academia – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO, Biomedical Engineers, Head of External Collaboration
Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer, Advisor for Toxicology

Healthcare Payment & Revenue Integrity Summit
2023-02-08 - 2023-02-09 | ORLANDO, FLORIDA
Introducing the only industry forum exclusively bringing together key decision-makers, within health insurers and providers, who are responsible for payment and revenue integrity, value-based payment, and networking relations.
At a time when both payers and providers are evaluating and streamlining internal payment and revenue integrity processes, this networking conference has been established to breakdown silos, by promoting discussion between clinical, coding, revenue cycle and payment departments to facilitate the development of efficient, value-based healthcare systems.
To know more visit: https://healthcarepaymentrevenueintegritysummit.com

14th Annual RNA Therapeutics Conference
2023-02-08 - 2023-02-09 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
SAE Media Group invites you to join the 14th Annual RNA Therapeutics Conference, taking place on 8 and 9 February 2023, in London, UK.
Building on the success of previous years, the RNA Therapeutics Conference will bring together industry experts from leading pharma and biotech companies to provide an expert and holistic view on the latest developments of the industry.
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.
With Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field.
This year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development.
Benefits of attending:

Explore how mRNA leads the way in the genetic medicine space as the next generation of novel drug modalities
Investigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics
Enhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech, Neuway Pharma and Ethris GmbH
Engage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory, neurodegenerative, and infectious diseases

Who should attend:

Directors of novel RNA therapies
CEOs
Senior and expert scientists
Chief Medical Officers
Chief Technical Officers
Senior Vice Presidents
Global Heads of mRNA R&D
Global Medical Directors
Heads of Translational Medicine
Director, Clinical Pharmacology
Global Head of RNA and Targeted Therapeutics
Clinical Science Director
Head of Biology
Director, Genetic Medicine
Associate Director

EARLY-BIRD RATES:

REGISTER BY 31ST OCTOBER AND SAVE £400
REGISTER BY 3OTH NOVEMBER AND SAVE £200
REGISTER BY 16TH DECEMBER AND SAVE £100
